Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Elliquis

- PMLiVE

Cellectis gets big pharma partners for CAR-T therapy

Pfizer, Servier and Cellectis in three-way deal to develop CAR-T immunotherapy

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

Bristol-Myers Squibb (BMS) building

BMS agrees to buy Cardioxyl for heart failure drug

Willpay up to $2bn for the US-based company

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy receives additional FDA approval

Gives the nod for Yervoy as adjuvant treatment option for melanoma

- PMLiVE

Allergan/Pfizer takeover talks confirmed

Talks still in early stage with no certainty of deal

- PMLiVE

Is Pfizer eyeing a merger with Allergan?

Combined company value could be $330bn

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

- PMLiVE

Pfizer’s investigational leukaemia drug wins breakthrough status

Puts inotuzumab ozogamacin in line for development incentives

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

Bristol-Myers Squibb (BMS) building

BMS signs $1.74bn deal to boost immuno-oncology portfolio

Gainsaccess to Five Prime Therapeutics CSF1R antibody programme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links